Le Lézard
Classified in: Health, Science and technology
Subjects: CALENDAR OF EVENTS, Conference Calls/ Webcasts

Goodness Growth Holdings to Release First Quarter 2024 Results on May 7, 2024


MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a cannabis company committed to providing safe access, quality products and great value to its customers, today announced that it will release its financial results for its first quarter ended March 31, 2024 on Tuesday, May 7, 2024 after the market closes.

Goodness Growth management will host a conference call with the investment community that day, Tuesday, May 7, 2024 at 4:30 p.m. ET (3:30 p.m. CT) to discuss its results. Interested parties may attend the conference call by dialing 1-800-715-9871 (Toll-Free) (US and Canada) or 1-646-307-1963 (Toll) (International) and referencing conference ID number 3718174.

A live audio webcast of this event will also be available in the Events & Presentations section of the Company's Investor Relations website and via the following link:
https://events.q4inc.com/attendee/586704075.

About Goodness Growth Holdings, Inc.

Goodness Growth Holdings, Inc. is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. Today, the Company is licensed to grow, process, and/or distribute cannabis in four markets and operates 14 dispensaries in three states. For more information about Goodness Growth Holdings, please visit www.goodnessgrowth.com.

Contact Information

Investor Inquiries:Media Inquiries:
Sam GibbonsAmanda Hutcheson
Managing DirectorCorporate Communications
[email protected][email protected]
(612) 314-8995(919) 815-1476



These press releases may also interest you

at 18:05
Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
Red Door Community Raises more than $300,000 at Their Annual Luncheon Celebrating Women Working and Living with Cancer
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Easy Eats Pandemanila brand Kalihim (Philippine Bread Rolls) recalled due to undeclared egg
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
Industrial Automation Market In Life Sciences Industry size is set to grow by USD 5.06 bn from 2024-2028, growing global demand for healthcare services to boost the market growth, Technavio
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
MODULAR ATP Study of the mCRMtm System Meets Primary Safety and Efficacy Endpoints
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

More news about Health...


News published on and distributed by: